

DEPARTMENT OF HEALTH AND HUMAN SERVICES



Stacie Weeks, JD MPH Administrator

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.

Silver State Scripts Board Meeting Minutes

Date of Meeting: Thursday, March 21, 2024, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and

Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record	Notes					
1. Closed Executive Session							
a. Call to Order and Roll Call	Chairperson Mark Decerbo called the me March 21, 2024.	Chairperson Mark Decerbo called the meeting to order at 1:00 p.m. on March 21, 2024.					
	 Chairperson Decerbo took the roll. Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm. D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD 	Present D D D D D D D D D D D D D	Absent	 Medicaid Pharmacy Director Clemons, Roshanda, MD, Medicaid Medical Director Flowers, Ellen, Social Services Program Specialist II Renee Sweeney, Social Services Program Specialist III supervisor NMAP Staff Present were as			
				follows:			

			 Johnson, Tory, Health Program Manager II Prime Staff Present were as follows: Mishra, Raj, Pharm.D., Clinical Account Manager Kim, James, Pharm.D., Dir. Clinical Account Services
			 Brittany Deoliveira, Pharm.D., Clinical Account Manager Martinez, Chris, Sr. Business Analyst Perez, Melissa, Sr. Business Analyst
b.	Financial Review of Drug Classes with Proposed Changes	Chairperson Decerbo directed Dr. Raj Mishra to proceed with the Financial Review of Drug classes with proposed changes up for review. Dr. Mishra reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting. Dr. Mishra presented the financial review of the established drug classes being reviewed due to the release of new drugs, noting the products with	
		proposed changes in PDL status. • Phosphate Binding Agents Dr. Mishra presented the financial review of the established drug classes being reviewed due to the release of new generics, noting the products with proposed changes in PDL status. • Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations	

Dr. Mishra presented the financial review of the New Drug Classes Being Reviewed for Proposed Addition, noting the products with proposed changes in PDL status. • Uterine Disorder Treatments Dr. Mishra presented the financial review of the established drug classes with proposed changes, noting the products with proposed changes in PDL status. • ADHD • Otic Quinolones • Beta-Blockers • Serotonin-Receptor Agonists (Triptans) • Ophthalmic Anti-infective/Anti-inflammatory Combinations • Immunomodulators: Atopic Dermatitis 2. Open Public Meeting a. Call to Order and Roll Call Chairperson Decerbo called the meeting to order at 1:55 p.m. on March 21, 2024. A quorum was present. DHCFP Staff Present wer follows: • Duncan, Keiko, Pharm Medicaid Pharmacy Director	
• Immunomodulators: Atopic Dermatitis 2. Open Public Meeting a. Call to Order and Roll Call Chairperson Decerbo called the meeting to order at 1:55 p.m. on March 21, 2024. A quorum was present. • DHCFP Staff Present were follows: • Duncan, Keiko, Pharm Medicaid Pharmacy	
2. Open Public Meeting a. Call to Order and Roll Call Chairperson Decerbo called the meeting to order at 1:55 p.m. on March 21, 2024. A quorum was present. DHCFP Staff Present wer follows: • Duncan, Keiko, Pharm Medicaid Pharmacy	
a. Call to Order and Roll Call Chairperson Decerbo called the meeting to order at 1:55 p.m. on March 21, 2024. A quorum was present. DHCFP Staff Present wer follows: • Duncan, Keiko, Pharm Medicaid Pharmacy	
21, 2024. A quorum was present. follows: Duncan, Keiko, Pharr Medicaid Pharmacy	
	mD,
Chairperson Decerbo took the roll. • Clemons, Roshanda, Present Absent Medicaid Medical Di	•
Mark Decerbo, Pharm.D., Chair □ Flowers, Ellen, Social	
Kate Ward, Pharm.D., Vice Chair □ Services Program	ı
Joseph Adashek, MD Specialist II	
Mark Crumby, Pharm. D. □ □ Renee Sweeney, Sociology	cial
Flizabeth Gonzalez, Pharm D. 🖂 Services Program	
Specialist III, Supervis Sapandeep Khurana, MD	isor
■ Isabella Niezborala, Pharm.D. □ □	ro as
Leana Ramirez, Pharm.D.	ic as
■ Aditi Singh, MD	

			Prime Staff Present were as follows: Mishra, Raj, Pharm.D., Clinical Account Manager Kim, James, Pharm.D., Dir. Clinical Account Services Brittany Deoliveira, Pharm.D., Clinical Account Manager Martinez, Chris, Sr. Business Analyst Perez, Melissa, Sr. Business Analyst The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured
b.	Approval for previous Meeting Minutes from December 14, 2023.	By unanimous consent, the minutes were approved.	ist's decuracy is flot assured
c.	Public Comments	Telephonic and web comment was called for, and the phone lines were opened.	
	Status Hadata by DUSER	No public comments were provided.	
u.	Status Update by DHCFP	 Medicaid Pharmacy Director, Dr. Keiko Duncan, provided an announcement. I did want to bring attention to one of our new team members that has joined our Pharmacy Services unit, Renee Sweeney, as a 	

			program specialist and we continue to recruit for two other open positions.
	e. S	tatus Update by NMAP	No announcement was provided.
3.	Clinic	cal Presentations	
	a	or Possible Action: Discussion nd possible adoption of hosphate Binding Agents.	
	i.	<u>Public comment</u>	Telephonic and web comment was called for, and the phone lines were opened.
			No public comment was provided.
	ii.	Drug class review presentation by Prime.	Dr. Mishra discussed Xphozah, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.
			Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.
	iii.	Discussion by Board and action by Board to approve clinical/therapeutic	Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent presented by Prime, and Board Member Elizabeth Gonzalez seconded the motion.
		equivalency of agents in class.	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):
			Yes No Abst.
			Mark Decerbo, Pharm.D., Chair
			■ Kate Ward, Pharm.D., Vice Chair □ □ □ ■ Joseph Adashek, MD □ □ □ □ □

ĺ			Mark Crumby, Pharm.D.	\boxtimes				
			• Elizabeth Gonzalez, Pharm.D.	\boxtimes				I
			 Sapandeep Khurana, MD 	\boxtimes				I
			 Isabella Niezborala, Pharm.D. 	\boxtimes				I
			 Leana Ramirez, Pharm.D. 	\boxtimes				I
			 Aditi Singh, MD 	×				<u> </u>
	iv.	Presentation of	Dr. Mishra recommended adding X	-			preferred	I
		recommendations for PDL	and removing Renagel due to manu	ıfacture	r disco	ntinued.		I
		inclusion by Prime.						I
ļ	٧.	Discussion by Board and	Chairperson Decerbo moved to app	rovo +h	n nron	osed change	ac ac	<u> </u>
	٧.	action by Board for	presented by Prime and Board Men			_		I
		approval of drugs for				seconded ti	ne modon.	I
		inclusion on the PDL.	A vote was taken, and the results w	ere as fo	ollows	from memb	ers in	I
			attendance (in favor, against, and a					I
								I
				Yes	No	Abst.		I
			 Mark Decerbo, Pharm.D., Chair 	\boxtimes				I
			Kate Ward, Pharm.D., Vice Chair	\boxtimes				I
			 Joseph Adashek, MD 			\boxtimes		I
			 Mark Crumby, Pharm.D. 	\boxtimes				I
			• Elizabeth Gonzalez, Pharm.D.	\boxtimes				I
			 Sapandeep Khurana, MD 	\boxtimes				I
			 Isabella Niezborala, Pharm.D. 	\boxtimes				I
			 Leana Ramirez, Pharm.D. 	\boxtimes				I
			Aditi Singh, MD	\boxtimes				<u> </u>
j		r Possible Action: Discussion						
		d possible adoption of						I
		dium-Glucose Co-						I
		ansporter 2 (SGLT2)						I
	Inl	hibitors and Combinations.						I
١								I

	Dublic comment	Talanhania and mahasanan satura	111 ^		Alexandrana Bases		
i.	<u>Public comment</u>	Telephonic and web comment was called for, and the phone lines were opened.					
		opened.					
		No public comment was provided.					
			no public confinent was provided.				
ii.	9	Dr. Mishra discussed dapagliflozin a					
	presentation by Prime.	new product within this drug class.	-		· ·		
		the drug class and noted the indica	tion, me	echanis	m of action, and		
		efficacy studies.					
		Dr. Mishra recommended the Board	d consid	ler the	class clinically and		
		therapeutically equivalent.			•		
ii	iii. Discussion by Board	Board member Gonzalez moved to	-		•		
	and action by Board to	therapeutically equivalent presente	-	ime an	d Board Member		
	approve clinical/therapeutic	Sapandeep Khurana seconded the r	notion.				
	equivalency of agents	A vote was taken, and the results w	ere as fo	ollows	from members in		
	in class.	attendance (in favor, against, and a					
			Yes	No	Abst.		
		Mark Decerbo, Pharm.D., Chair	\boxtimes				
		Kate Ward, Pharm.D., Vice Chair	\boxtimes				
		Joseph Adashek, MD			\boxtimes		
		Mark Crumby, Pharm.D.	\boxtimes				
		Elizabeth Gonzalez, Pharm.D.	\boxtimes				
		Sapandeep Khurana, MD	\boxtimes				
		■ Isabella Niezborala, Pharm.D. □ □ □					
		Leana Ramirez, Pharm.D.	\boxtimes				
		Aditi Singh, MD	X		<u> </u>		
	iv. Presentation of	Dr. Mishra recommended adding da					
	recommendations for PDL inclusion by Prime.	dapagliflozin/metformin ER to the F	'DL as n	on-pre	nerrea.		
	T DE IIICIUSION DY PINNE.						

	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairperson Decerbo moved to approve the proposed changes as presented by Prime and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
			Yes	No	Abst.		
		 Mark Decerbo, Pharm.D., Chair 	\boxtimes				
		Kate Ward, Pharm.D., Vice Chair	\boxtimes				
		 Joseph Adashek, MD 					
		 Mark Crumby, Pharm.D. 	\boxtimes				
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes				
		 Sapandeep Khurana, MD 	\boxtimes				
		 Isabella Niezborala, Pharm.D. 	\boxtimes				
		 Leana Ramirez, Pharm.D. 	\boxtimes				
		 Aditi Singh, MD 	\boxtimes				
	ossible Action: Discussion						
•	ossible adoption of						
Uterii	ne Disorder Treatment.						
i. <u>F</u>	Public Comment	Telephonic and web comment was opened.	called f	or, and	the phone lines were		
		Public comment was provided by Je Pharma America.	Public comment was provided by Jeffrey Nesheim from Sumitomo				
	Drug class review presentation by Prime.	Dr. Mishra recommended the Boar therapeutically equivalent.	d consid	ler the	class clinically and		
ā	Discussion by Board and action by Board to approve	Board Member Gonzalez moved to therapeutically equivalent presents Leanna Ramirez seconded the moti	ed by Pri				

	clinical/therapeutic equivalency of agents in	A vote was taken, and the results w	oro as f	allows	from mombors in	
	class.	attendance (in favor, against, and a				
		Ι				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 			\boxtimes	
		Mark Crumby, Pharm.D.	\boxtimes			
		Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		• Isabella Niezborala, Pharm.D.	\boxtimes			
		 Leana Ramirez, Pharm.D. 	\boxtimes			
		Aditi Singh, MD	X			
iv.		Dr. Mishra recommended adding U				
	recommendations for	class with Myfembree, Oriahnn and Orilissa as preferred.				
	PDL inclusion by Prime.					
V	Discussion by Board and	Board Member Gonzalez moved to	annrovi	e the n	ronosed changes as	
••	action by Board for	presented by Prime and Chairperso			•	
	approval of drugs for	,				
	inclusion on the PDL.	A vote was taken, and the results w	ere as fo	ollows	from members in	
		attendance (in favor, against, and a	bstentic	ons wh	ere applicable):	
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		Joseph Adashek, MD			\boxtimes	
		Mark Crumby, Pharm.D.	\boxtimes			
		Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		 Isabella Niezborala, Pharm.D. 	\boxtimes			

	 Leana Ramirez, Pharm.D. 	\boxtimes			
	Aditi Singh, MD	X			
D. For Possible Action: Discussion and possible adoption of ADHD Agents.					
i. <u>Public Comment</u>	Telephonic and web comment was opened.	called fo	or, and	the phone li	nes were
	No public comment was provided.				
ii. Drug class review presentation by Prime.	Dr. Mishra recommended the Board therapeutically equivalent.	d consid	er the	class clinicall	y and
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	therapeutically equivalent presente Khurana seconded the motion. A vote was taken, and the results w	Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Prime and Board Member Khurana seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):			
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	\boxtimes			
	Kate Ward, Pharm.D., Vice Chair	\boxtimes			
	Joseph Adashek, MD			\boxtimes	
	Mark Crumby, Pharm.D.	\boxtimes			
	Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	Sapandeep Khurana, MD	\boxtimes			
	 Isabella Niezborala, Pharm.D. 	\boxtimes			
	 Leana Ramirez, Pharm.D. 	\boxtimes			
	Aditi Singh, MD	\boxtimes			

	r. Presentation of recommendations for PDL inclusion by Prime. r. Board Member comments	Dr. Mishra recommended adding N preferred. Dr. Khurana provided a comment regeneric is non-preferred.				
vi	i. Discussion by Board and	SSSB will bring the topic of Vyvanse Chairperson Decerbo moved to app				
	action by Board for approval of drugs for	presented by Prime and Board Mer				
	inclusion on the PDL.	A vote was taken, and the results w attendance (in favor, against, and a				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	×			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 			\boxtimes	
		Mark Crumby, Pharm.D.	\boxtimes			
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		 Sapandeep Khurana, MD 	\boxtimes			
		• Isabella Niezborala, Pharm.D.	\boxtimes			
		 Leana Ramirez, Pharm.D. 	\boxtimes			
		 Aditi Singh, MD 	\boxtimes			
а	or Possible Action: Discussion nd possible adoption of Otic Quinolones.					
i	i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.				
		No public comment was provided.				

-						
	ii. Drug class review presentation by Prime.	Dr. Mishra recommended the Board therapeutically equivalent.	d			
	iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Gonzalez moved to therapeutically equivalent presente seconded the motion. A vote was taken, and the results wattendance (in favor, against, and a	d			
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 			\boxtimes	
		Mark Crumby, Pharm.D.	\boxtimes			
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		Isabella Niezborala, Pharm.D.	\boxtimes			
		Leana Ramirez, Pharm.D.	\boxtimes			
L		Aditi Singh, MD	\boxtimes			
	iv. Presentation of recommendations for PDL inclusion by Prime	Dr. Mishra recommended moving c non-preferred to preferred.	Dr. Mishra recommended moving ciprofloxacin/dexamethasone from			
	 v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL. 	Chairperson Decerbo moved to app presented by Prime and Board Men	tion.			
		A vote was taken, and the results wattendance (in favor, against, and a				
			Yes	No	Abst.	
l		 Mark Decerbo, Pharm.D., Chair 	\boxtimes			

	Kate Ward, Pharm.D., Vice Chair	\boxtimes					
	 Joseph Adashek, MD 			\boxtimes			
	Mark Crumby, Pharm.D.	\boxtimes					
	Elizabeth Gonzalez, Pharm.D.	\boxtimes					
	Sapandeep Khurana, MD	\boxtimes					
	 Isabella Niezborala, Pharm.D. 	\boxtimes					
	 Leana Ramirez, Pharm.D. 	\boxtimes					
	Aditi Singh, MD	\boxtimes					
F. For Possible Action: Discussion and possible adoption of Beta-Blockers.							
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.						
	No public comment was provided.						
ii. Drug class review presentation by Prime.	Dr. Mishra recommended the Boar therapeutically equivalent.						
iii. Discussion by Board and	Vice Chair Ward moved to accept the	he class	as clin	ically an	d		
action by Board to	therapeutically equivalent presente	ed by Pr	ime an	d Board	Member		
approve clinical/therapeutic	Gonzalez seconded the motion.						
equivalency of agents in	A vote was taken, and the results w						
class.	attendance (in favor, against, and abstentions where applicable):						
		Yes	No	Abst.			
	Mark Decerbo, Pharm.D., Chair	\boxtimes					
	Kate Ward, Pharm.D., Vice Chair	\boxtimes					
	Joseph Adashek, MD			\boxtimes			
	 Mark Crumby, Pharm.D. 	\boxtimes					

	Elizabeth Gonzalez, Pharm.D.	\boxtimes				
	Sapandeep Khurana, MD	\boxtimes				
	 Isabella Niezborala, Pharm.D. 	\boxtimes				
	 Leana Ramirez, Pharm.D. 	\boxtimes				
	Aditi Singh, MD	\boxtimes				
			_			
iv. Presentation of	Dr. Mishra recommended removing					
recommendations for PDL	manufacture discontinue and movi	-				
inclusion by Prime.	preferred to preferred. Also recomi pindolol from preferred to non-pre		_			
	preferred and moving the generic f					
	preferred and moving the generic i	10111 1101	i preie	rrea to pren	zii cu.	
v. Discussion by Board and	Chairperson Decerbo moved to app	rove th	e prop	osed change	s as	
action by Board for	presented by Prime with the except		_		S	
approval of drugs for	preferred and Board Member Gonz	alez sec	onded	the motion.		
inclusion on the PDL.						
	A vote was taken, and the results w					
	attendance (in favor, against, and a	bsteritic	JIIS WII	ere applicab	ie).	
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	\boxtimes				
	Kate Ward, Pharm.D., Vice Chair	\boxtimes				
	 Joseph Adashek, MD 			\boxtimes		
	Mark Crumby, Pharm.D.	\boxtimes				
	Elizabeth Gonzalez, Pharm.D.	\boxtimes				
	Sapandeep Khurana, MD	\boxtimes				
	• Isabella Niezborala, Pharm.D.	\boxtimes				
	 Leana Ramirez, Pharm.D. 	\boxtimes				
	Aditi Singh, MD	X				
G. For Possible Action: Discussion						
and possible adoption of						

Seroto (Tripta	onin-Receptor Agonists ans).							
i. <u>P</u> u	ublic Comment	Telephonic and web comment was called for, and the phone lines were opened.						
		No public comment was provided.						
	ug class review esentation by Prime.	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.						
ac ap cli ec	iscussion by Board and ction by Board to opprove inical/therapeutic quivalency of agents in ass.	Chairperson Decerbo moved to accept the class as clinically and therapeutically equivalent presented by Prime and Vice Chair Ward seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):						
			Yes	No	Abst.			
		Mark Decerbo, Pharm.D., Chair	\boxtimes					
		 Kate Ward, Pharm.D., Vice Chair 	\boxtimes					
		 Joseph Adashek, MD 			\boxtimes			
		 Mark Crumby, Pharm.D. 	\boxtimes					
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes					
		 Sapandeep Khurana, MD 	\boxtimes					
		• Isabella Niezborala, Pharm.D.	\boxtimes					
		 Leana Ramirez, Pharm.D. 	\boxtimes					
		Aditi Singh, MD	X					
	resentation of	Dr. Mishra recommended removing						
	commendations for PDL clusion by Prime.	due to manufacture discontinue an preferred to non-preferred. Also re from non-preferred to preferred.						

v. Board Member comments	Dr. Ramirez provided a comment regarding not having a nasal spray option as preferred.						
vi. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Ramirez moved to a presented by Prime with the except spray from non-preferred to prefer the motion.						
	A vote was taken, and the results wattendance (in favor, against, and a						
		Yes	No	Abst.			
	Mark Decerbo, Pharm.D., Chair	\boxtimes					
	Kate Ward, Pharm.D., Vice Chair	\boxtimes					
	 Joseph Adashek, MD 	\boxtimes					
	 Mark Crumby, Pharm.D. 						
	• Elizabeth Gonzalez, Pharm.D.	■ Elizabeth Gonzalez, Pharm.D. □ □ □					
	 Sapandeep Khurana, MD 	Sapandeep Khurana, MD ⊠ □ □					
	 Isabella Niezborala, Pharm.D. 	\boxtimes					
	 Leana Ramirez, Pharm.D. 						
	 Aditi Singh, MD 	■ Aditi Singh, MD □ □ □					
 H. For Possible Action: Discussion and possible adoption of Ophthalmic Anti-inflammatory Combinations. 							
i. <u>Public Comment</u>	Telephonic and web comment was opened.	called f	or, and	the phone lines were			
	No public comment was provided.						

	Drug class review presentation by Prime.	Dr. Mishra recommended the Board therapeutically equivalent.				
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chairperson Decerbo moved to accomply the the therapeutically equivalent presented seconded the motion. A vote was taken, and the results we attendance (in favor, against, and a seconded the motion).				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	×			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 			\boxtimes	
		Mark Crumby, Pharm.D.				
		• Elizabeth Gonzalez, Pharm.D.				
		Sapandeep Khurana, MD				
		• Isabella Niezborala, Pharm.D.				
		• Leana Ramirez, Pharm.D.				
		Aditi Singh, MD	\boxtimes			
iv.	Presentation of recommendations for PDL inclusion by Prime.	Dr. Mishra recommended moving Z and moving tobramycin/dexametha preferred.				
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Gonzalez moved to presented by Prime and Board Mem A vote was taken, and the results we attendance (in favor, against, and a				
			Yes	No	Abst.	

	Mark Decerbo, Pharm.D., Chair	\boxtimes				
	Kate Ward, Pharm.D., Vice Chair	\boxtimes				
	 Joseph Adashek, MD 			\boxtimes		
	Mark Crumby, Pharm.D.	\boxtimes				
	Elizabeth Gonzalez, Pharm.D.	\boxtimes				
	Sapandeep Khurana, MD	\boxtimes				
	• Isabella Niezborala, Pharm.D.	\boxtimes				
	Leana Ramirez, Pharm.D.	\boxtimes				
	Aditi Singh, MD	\boxtimes				
I. For Possible Action: Discussion and possible adoption of Immunomodulators: Atopic Dermatitis.						
i. <u>Public Comment</u>	Telephonic and web comment was opened. Public comment was provided by V Medical Affairs.					
ii. Drug class review presentation by Prime.	Dr. Mishra recommended the Boar therapeutically equivalent.					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Vice Chair Ward moved to accept the therapeutically equivalent presents Khurana seconded the motion. A vote was taken, and the results wattendance (in favor, against, and a					
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	×				
	Kate Ward, Pharm.D., Vice Chair	\boxtimes				

	Joseph Adashek, MD			\boxtimes		
	Mark Crumby, Pharm.D.	\boxtimes				
	Elizabeth Gonzalez, Pharm.D.	\boxtimes				
	Sapandeep Khurana, MD	\boxtimes				
	• Isabella Niezborala, Pharm.D.	\boxtimes				
	Leana Ramirez, Pharm.D.	\boxtimes				
	Aditi Singh, MD	\boxtimes				
iv. Presentation of	Dr. Mishra recommended removing					
recommendations for PDL	manufacture discontinue and movi	ng its ge	eneric t	acrolimu	s topical from	
inclusion by Prime.	non-preferred to preferred.					
	Note: This class is currently in the to	opical a	nti-infl	ammator	v agents	
	section of the PDL giving we have m	•				
	class its being moved to the genera		-			
	PDL.					
v. Discussion by Board and	Board Member Gonzalez moved to		-	-	_	
action by Board for	presented by Prime and Vice Chair Ward seconded the motion.					
approval of drugs for inclusion on the PDL.	A vote was taken, and the results were as follows from members in					
inclusion on the FDL.	attendance (in favor, against, and a					
	attendance (iii ravor, against, and a			c. c appii		
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	\boxtimes				
	Kate Ward, Pharm.D., Vice Chair	\boxtimes				
	Joseph Adashek, MD			\boxtimes		
	Mark Crumby, Pharm.D.	\boxtimes				
	Elizabeth Gonzalez, Pharm.D.	\boxtimes				
	Sapandeep Khurana, MD	\boxtimes				
	Isabella Niezborala, Pharm.D.	\boxtimes				

J. Prime Reports	 Leana Ramirez, Pharm.D. Aditi Singh, MD New Drugs to Market and New Line Extensions Reflection On the Horizon for 2024 Gene therapy/Metabolic — atidarsagene autotemcel Respiratory — ensifentrine Insulin icodec SC Infectious disease — respiratory syncytial virus (RSV) vaccine, mRNA-1345 Sotatercept SC Legislation Update: Provision in the American Rescue Plan (ARP) Act of 2021 	
K. Closing Discussioni. Public comments on any subject	No public comments were provided.	
ii. Date and location of the next meeting.	Date: June 20, 2024 Location: Courtyard by Marriott Las Vegas Convention Center 3275 Paradise Road, Las Vegas, NV, 89109	
iii. Adjournment	Chairperson Decerbo adjourned the meeting at 3:07 PM.	

Attachment A – Members of the Public in Attendance

Amy Shogren	Kim Eggert	Ryan A Roa	JJ Roth	Jeana Colabianchi
Elisa Ashton [SCGUS]	Luke Lim	Sabrina Schnur	Valarie Ng	Jake Douglas
Ashley Dihn	Mark Funkhouser	Sara Stolfus	Eric Perry	
Jeffrey Nesheim	Michael	Tania Guzman	Lee Stout	
Karen Ou	Pauline Salla	Tray Abney	Aaron Girvin	

Attachment B – Submitted Written Comment

None